argenx agrees to buy California biotech Unnatural Products for up to $1.15bn
The Belgian-Dutch drugmaker is buying oral peptide technology to complement its antibody expertise and broaden its pipeline beyond Vyvgart.

argenx has agreed to acquire Unnatural Products, a biotechnology company based in Santa Cruz, California, for up to approximately $1.15 billion, adding oral peptide technology as it works to broaden its immunology pipeline.
The agreement includes $550 million in upfront cash and up to $595 million in payments tied to development and regulatory milestones, according to a November 9 report by Briefs. The Belgian-Dutch drugmaker already holds a minority stake in the privately held company, and the two businesses have previously worked together.
For argenx, the US acquisition is principally a technology move: it would bring a complementary drug-development capability into a business built around antibody engineering. The strategic opportunity is to develop some medicines as pills rather than injectables, while reducing the company’s reliance on its blockbuster medicine Vyvgart.
Adding an oral route to the pipeline
Unnatural Products’ oral peptide capability fits alongside argenx’s existing antibody expertise, according to the report. Barclays analysts described the agreement as “a sensible strategic transaction,” pointing to the potential to develop some current experimental drugs and future candidates as pills.
That possibility is the central rationale for the purchase, rather than an immediate addition to argenx’s marketed portfolio. The report does not identify which experimental programs might use the technology or give a timetable for bringing an oral candidate to market. The potential change in how medicines are administered remains a development opportunity, not an established outcome of the deal.
The transaction would also deepen an existing relationship. Moving from collaboration and minority ownership to an acquisition gives argenx a route to bring the US company’s technology into its own pipeline strategy, rather than simply maintaining an outside investment.
A second deal to broaden immunology
The agreement follows argenx’s July deal to acquire Forte Biosciences for about $2.2 billion, which Briefs reported brought a potential therapy for vitiligo and celiac disease, with possible applications across other autoimmune conditions. Unnatural Products marks its second major deal of the year.
The two transactions address different parts of the diversification effort: Forte adds a potential therapy, while Unnatural Products adds technology that could support existing and future candidates. The California deal therefore expands argenx’s development capabilities in the United States, rather than representing a conventional commercial market entry.
Just over half of the maximum consideration for Unnatural Products depends on development and regulatory milestones. That structure leaves a substantial portion of the purchase price contingent on scientific and regulatory progress. The strategic test will be whether argenx can translate the acquired capability into viable medicines that broaden its business beyond Vyvgart.


